ArticleLiver cancer2026
Real-World Treatment Patterns and Clinical Outcomes in Patients with Unresectable Hepatocellular Carcinoma: Results from the OREIOS Study.
Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05239507 (A Multicountry, Multicentre, Noninterventional, Retrospective Study to Describe the Real-world Management Outcomes in Patients With Unresectable Hepatocellular Carcinoma), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicountry, Multicentre, Noninterventional, Retrospective Study to Describe the Real-world Management Outcomes in Patients With Unresectable Hepatocellular Carcinoma
Who cites it
2 citing papers in PubMed.
- Immune-checkpoint inhibitors for advanced hepatocellular carcinoma in Child-Turcotte-Pugh-B cirrhosis: a liver-centric approach to outcomes beyond tumor progression.Hepatology international · 2026Review
- Systemic treatment patterns and clinical outcomes in hepatocellular carcinoma: A multicenter real-world study from China (STAR-HCC).JHEP reports : innovation in hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: OREIOS (NCT05239507) study determined the clinical characteristics, management patterns, and survival outcomes in patients with unresectable HCC (uHCC) from 12 countries across Asia, Latin America, and Middle East and Africa. Methods: This non-interventional, retrospective study enrolled patients with Barcelona Clinic Liver Cancer (BCLC) stage B or C unresectable or advanced/metastatic hepatocellular carcinoma (HCC) at index date, diagnosed between January 2017 and December 2019. The primary outcomes were median overall survival (mOS) and landmark survival (12 and 24 months) and secondary outcomes were clinicodemographic characteristics, treatment patterns, and median progression-free survival (mPFS). Results: A total of 1,116 patients (median [range] age: 63.0 [18.0-97.0] years) were recruited; 83.2% (929/1,116) were males, 49.5% (422/852) were current/ex-smokers, and 21.3% (122/572) consumed alcohol. At the index date, 22.3% (249/1,116) and 77.7% (867/1,116) of patients presented with BCLC stage B and C, respectively, with main portal vein invasion in 23.5% (263/1,116), >50% liver involvement in 23.1% (250/1,082), and extrahepatic metastases in 48.5% (541/1,116). Transarterial chemoembolization was performed before and after the index dates in 22.9% (255/1,112) and 20.8% (232/1,116) of patients, respectively. In the first-line of therapy (LOT), majority of patients received tyrosine multikinase inhibitors (TKIs) - sorafenib (68.3% [684/1,002] and lenvatinib (10.2% [102/1,002]). Irrespective of LOT, the mPFS and mOS were 6.1 (95% confidence interval [CI]: 5.5-6.7) and 13.1 (95% CI: 11.6, 14.1) months for the overall cohort. The survival rates at 12 and 24 months for the overall cohort were 52.1% (95% CI: 49.1-55.1) and 30.6% (95% CI: 27.8-33.4). Conclusion: Our study provides retrospective view of treatment strategies in patients with advanced uHCC prior to advent of immunotherapy and combination therapy. Majority of patients received TKIs, as per then recommended and available treatment options. The mOS in our study was similar to that observed in pivotal clinical trials for TKIs. With novel agents and combination therapies being approved for uHCC, integrating them into routine care is important to improve survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.